Fusion Antibodies PLC represents a set of core values and a corporate philosophy that guide its operations. The company's values include innovation, quality, and collaboration. Fusion Antibodies PLC is committed to driving innovation in antibody discovery and development, delivering high-quality services and products to its clients. The company fosters a collaborative approach, working closely with partners and customers to achieve mutual success. Emphasizing integrity and ethical practices, Fusion Antibodies PLC maintains a customer-centric focus and seeks to continuously improve its operations and offerings. Through its values and corporate philosophy, Fusion Antibodies PLC strives to make a positive impact in the field of antibody research and healthcare.

Fusion Antibodies PLC is primarily present in the United Kingdom and Ireland.

Fusion Antibodies PLC, a leading biotechnology company, has achieved significant milestones in its journey. Notably, the company successfully listed on London's AIM market in December 2017, raising funds to expand its operations and pursue strategic growth opportunities. Furthermore, Fusion Antibodies has built a strong reputation as a specialist Contract Research Organization (CRO) with expertise in antibody engineering and development. The company has continuously advanced its proprietary antibody optimization platform, which enables the discovery and development of unique antibody therapeutics. Fusion Antibodies has also established several key partnerships and collaborations in the biopharmaceutical industry, reinforcing its position as a trusted, innovative player in the field.

Fusion Antibodies PLC is a biotechnology company specializing in the discovery and development of antibodies for pharmaceutical, diagnostic, and research purposes. Founded in 2001, Fusion Antibodies has established itself as a leader in antibody engineering and humanization, helping clients optimize their antibody candidates for therapeutic use. With a team of experienced scientists and state-of-the-art facilities, the company offers a range of services, including antibody production, cell line development, and antibody engineering. Fusion Antibodies PLC has formed strategic partnerships with renowned pharmaceutical companies, contributing to the advancement of novel therapies. With a strong history and track record, Fusion Antibodies PLC continues to drive innovation in the field of antibody therapeutics.

Some of the main competitors of Fusion Antibodies PLC in the market include Abcam PLC, GenScript Biotech Corporation, and Abzena PLC.

Fusion Antibodies PLC is primarily active in the biotechnology and pharmaceutical industries.

The business model of Fusion Antibodies PLC revolves around providing advanced antibody discovery, engineering, and manufacturing services to pharmaceutical and biotechnology companies. Fusion Antibodies specializes in the development of antibodies for use in areas such as oncology, infectious diseases, and immuno-oncology. Their services include antibody humanization, antibody library generation, antibody engineering, and antibody manufacturing. Fusion Antibodies collaborates with clients to create custom solutions and optimize therapeutic antibody development. With their expertise in antibody technologies, Fusion Antibodies aims to support the development of novel drugs and therapies by delivering high-quality, cost-effective antibody products.

KGV Fusion Antibodies iznosi −0,26.

Koeficijent cijene i prometa Fusion Antibodies iznosi 0,69.

AlleAktien Qualitätsscore za Fusion Antibodies je 2/10.

Promet očekivana Fusion Antibodies iznosi 1,17 mil. GBP.

Dobit očekivana Fusion Antibodies iznosi −3,05 mil. GBP.

The company Fusion Antibodies PLC is a leading provider of antibody solutions and services on a global level. The company offers its customers access to a wide range of high-quality antibodies, proteins, and reagents, from antibody provision to services such as antibody development, manufacturing, and characterization. Fusion Antibodies PLC specializes in providing innovative and customized antibody solutions. The company has developed a wide range of antibody products that can be used in various applications, including custom antibodies to support research and development, as well as therapeutic antibodies for disease diagnosis and treatment. The company has extensive experience in antibody manufacturing and offers various services to support product development, including antibody purification and characterization, monoclonal antibody production, and antibody conjugate production for drug development. Fusion Antibodies PLC has also developed some new services that contribute to increasing productivity and shortening product development time. These include antibody cloning, antibody optimization, and antibody-protein fusion technology. These services are offered to meet the needs of both pharmaceutical companies and companies in the field of biotechnological research. The company has a wide range of manual and automated laboratory services and works closely with its customers to meet their specific requirements. This collaboration helps significantly accelerate research and development processes. Among all the offerings of Fusion Antibodies PLC, its innovative Fusion Express platform stands out. This technology enables faster and more efficient antibody development by incorporating antibodies into specialized expression systems. Fusion Antibodies PLC has also announced the acquisition of Innovate Biopharmaceuticals, Inc. - a company focused on developing new therapies for inflammatory diseases. Overall, Fusion Antibodies PLC offers its customers a comprehensive range of services and products for antibody development. The company is committed to always offering innovative solutions to meet the growing demand for product development. With its specialized laboratory services and experienced team of scientists and technicians that consider customer requirements, Fusion Antibodies PLC is a valuable resource for pharmaceutical companies, biotechnology companies, and research laboratories worldwide.

Fusion Antibodies isplaćuje dividendu od 0 GBP raspoređenu preko isplata godišnje.

Dividenda za Fusion Antibodies trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Fusion Antibodies je GB00BDQZGK16.

Oznaka burze tvrtke Fusion Antibodies je FAB.L.

U posljednjih 12 mjeseci Fusion Antibodies je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Fusion Antibodies će vjerojatno isplatiti dividendu u iznosu od 0 GBP.

Trenutni prinos dividende od Fusion Antibodies iznosi .

Fusion Antibodies isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Fusion Antibodies je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 GBP. To odgovara dividendnom prinosu od 0 %.

Fusion Antibodies se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Fusion Antibodies od 07. 08. 2024. u iznosu od 0 GBP, trebali ste imati dionicu u portfelju prije Ex-dana 07. 08. 2024..

Posljednja isplata dividende izvršena je 07. 08. 2024..

U godini 2023 su od Fusion Antibodies 0 GBP isplaćene kao dividende.

Dividende od Fusion Antibodies isplaćuju se u GBP.